Stock Watch: Oncology Dynamics Underscore Roche And AstraZeneca’s Contrasting Fortunes
Cancer Drug Sales Diverged In 2020 And Not Just Due To The Pandemic
Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.
